MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today ...

Starting later this year, Ouro intends to start a phase 1 clinical trial of its own, eyeing the development of the drug for ...